ISRCTN15124178已完成不适用
A study identifying which biomarkers are predictive of a good clinical response following treatment with Xolair in patients with severe asthma
Southampton University Hospitals NHS Trust0 个研究点目标入组 220 人开始时间: 2016年9月6日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 220
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Aged 18-70 years
- •2. Severe uncontrolled asthma (GINA step 4 and 5) despite daily treatment with high-dose inhaled corticosteroids (ICS) and long-acting beta agonists (LABA). (High-dose ICS will be a minimum twice daily dose of 800 mcg of beclomethasone dipropionate equivalent inhaler for at least 8 weeks before screening). Potential participants will need to fulfil the criteria for uncontrolled asthma as judged by their Asthma Control Questionnaire (ACQ) score =1.5 during the screening period.
- •3. Participants on maintenance treatment with oral corticosteroids will also be included and will also have to meet the same ACQ inclusion criterion (ACQ=1.5)
- •4. Atopic, as identified by positive skin prick test or in vitro reactivity to a perennial aeroallergen
- •5. Two or more documented severe asthma exacerbations within the previous 12 months that require courses of prednisolone, defined as increased asthma symptoms requiring treatment in the community or in hospital with systemic corticosteroid rescue therapy or an increase in daily oral corticosteroids for participants already on maintenance oral corticosteroids for >2 months
- •6. Frequent daytime symptoms or night-time awakenings
- •7. Reduced lung function (FEV1 <80%) recorded anytime within the past 2 years
- •8. IgE level of 30 to 1500 IU/mL
- •9. Body weight less than 150 kg
- •10. Able to give written informed consent prior to participation in the study, which includes ability to comply with the requirements and restrictions listed in the consent form
- •11. Able to read, comprehend, and write at a sufficient level to complete study related materials
排除标准
- •1.An exacerbation requiring treatment with systemic corticosteroids (or an increase in the baseline dose of OCS) within the 30 days before screening
- •2. Active lung disease other than asthma
- •3. Treatment with Xolair or another biologic in the 12 months before screening
- •4. Elevated serum IgE levels for reasons other than allergy (for example, parasite infections, the hyperimmunoglobulin E syndrome, the Wiskott–Aldrich syndrome, or bronchopulmonary aspergillosis)
- •5. The following medication is not allowed during the run-in and treatment period and should not have been taken for at least 3 months prior to screening: methotrexate, cyclosporine, intravenous immunoglobulin or immunosuppressant’s
- •6. Current smokeror having smoked in the past year. Ex-smokers will have to be confirmed by a negative cotinine test. If there is a history of smoking for >10 pack years, then asthma diagnosis should have been made before the age of 40 and objective evidence of reversibility of FEV1>12% and 200ml should be available [either previously recorded or done as part of screening for this study]. Potential participants where an asthma/COPD overlap is suspected should not be included.
- •7. The participant has a history of current recreational drug use or other allergy, which, in the opinion of the responsible physician, contra-indicates their participation
- •8. Female patient who is pregnant or lactating or up to 6 weeks post partum or 6 weeks cessation of breast feeding
- •9. Those participants who, in the opinion of the investigator, have a risk of non-compliance with study procedures
- •10. The participant has a recent history of incapacitating psychiatric disorders
- •11. History or current evidence of an upper or lower respiratory infection or symptoms (including common cold) within 4 weeks of baseline assessments (in such participant assessments should be deferred until after 4 weeks have lapsed from the cold)
研究者
相似试验
已完成
不适用
Exploratory study of biomarkers predicting response to nivolumab in non-small-cell lung canceron-small-cell lung cancerJPRN-UMIN000022505Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine200
已完成
不适用
Research for biomarkers to predict the effectiveness of zoledronic acid in metastatic bone tumorsPatients with bone metastases newly treated by zoledronic acidJPRN-UMIN000018556agoya University Graduate School and School of Medicine27
已完成
不适用
Research for biomarkers to predict the effectiveness of denosumab in metastatic bone tumorsPatients with bone metastases newly treated by denosumabJPRN-UMIN000019700agoya University Graduate School and School of Medicine40
已完成
不适用
Elucidation of biomarkers to predict the presence of coronary vulnerable plaqueJPRN-UMIN000009806agasaki University Graduate School of Biomedical Sciences200
已完成
不适用
Biomarker study; study to identify biomarkers for protein intake, a randomized, fully controlled feeding studyGeen aandoeningenUitscheiding van biomerkers na het eten van eiwit in het gezond menselijk lichaamBiomarkers of protein intakeNL-OMON36525Wageningen Universiteit25